Menu
← Oncology Approval Tracker
FDA DECISION ·
Darzalex Faspro + Kyprolis + dexamethasone
daratumumab and hyaluronidase-fihj with carfilzomib and dexamethasone · Janssen Biotech / Amgen
Open LinkedIn brief ↓1 min read · estimated
APPROVED USE
What FDA approved
Adults with relapsed or refractory multiple myeloma after one to three prior treatment lines.
LAMPGEN ANALYSIS
Why it matters
The regimen pairs subcutaneous daratumumab with carfilzomib and dexamethasone in previously treated myeloma.
What research teams should watch
Document the carfilzomib schedule and daratumumab route and track cardiac and infusion-related events across the combination.
PRIMARY RECORDS